The University of Michigan Regents Communication

Request for Action

Subject: Commercialization Agreements with the University

Action Requested: Approval of Commercialization Agreements

Preamble:

Statutory conflicts of interest situations were identified by Innovation Partnerships while reviewing commercialization agreements that then triggered a review by the Medical School Conflict of Interest Board ("Board") and/or the OVPR Conflict of Interest Committee ("Committee"). Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved.

These proposed commercialization agreements ("Agreements") fall under the State of Michigan Conflict of Interest Statute because employees of the University of Michigan ("University") have outside activities, relationships, or interests in the companies described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents ("Regents") of the University and approved in advance by a 2/3 vote.

Background:

These companies were formed to commercialize University technologies and desire to option, license, or reassign the University's rights associated with them. Innovation Partnerships selected these companies as University partners and negotiated the terms of the proposed agreements in accordance with University policy and its accepted licensing principles.

Agreement Terms Include:

The University will retain ownership of the optioned, licensed, or reassigned technologies and may continue to further develop and use them internally. No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreements. Standard disclaimers of warranties and indemnification apply, and the Agreements may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed, and additional conflict of interest review will be done as appropriate. Terms specific to each Agreement are described in Attachment A

Net Effect:

Innovation Partnerships has negotiated and finalized the terms of the option, license, or reassignment agreements for patents, technology, or content related to University technologies for particular fields of use. The companies will obtain the right to evaluate, use, and/or commercialize the University technologies. The net effects specific to each Agreement are described in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Board and/or the Committee. In light of this disclosure and our finding that the Agreements were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the Agreements between the University and the companies outlined in Attachment A.

Respectfully submitted,



Patricia Hurn

Interim Vice President for Research and Innovation

November 2026

Attachment

Attachment A

Agreement #1

License Agreement between the University and Loxagen, Inc.

Reviewed by the Medical School Conflict of Interest Board

Background:

Loxagen, Inc. was formed to commercialize small molecule 12LOX inhibitors to treat thrombotic disease.

Innovation Partnerships Intellectual Property File Information:

- **Number:** 2018-246
    - **Title:** Analogs of 12-LOX Inhibitor ML355 for Protection from Heparin-Induced Thrombocytopenia and Thrombosis
    - **Inventor:** Michael Holinstat

Net Effects:

- Worldwide exclusive
- Patents
- Human therapeutics
- Commercialization

Agreement Terms:

Loxagen, Inc. will:

- Retain the right to grant sublicenses
- Pay a royalty on sales
- Reimburse patent costs

The University:

- Will retain ownership of the licensed technology
- May receive equity in Loxagen, Inc.
- May retain the right to purchase more equity in Loxagen, Inc.

University Employee; University Title; Relationship with Loxagen, Inc.:

- Michael Holinstat; Professor of Pharmacology, Medical School; Owner

Agreement #2

License Agreement between the University and Motion Sync Technologies Inc.

Reviewed by the OVPR Conflict of Interest Committee

Background:

Motion Sync Technologies Inc. was formed to commercialize technologies that mitigate motion sickness for the transportation industry and desires to license the University's rights associated with the technology listed below.

Innovation Partnerships Intellectual Property File Information:

- **Number:** 2020-163
  - **Title:** PRE-ACT: Preemptively Controlled Active Seating, Restraint, and Wearable Technology to Mitigate Passenger Motion Sickness in Human/Computer Driven Vehicles
  - **Inventors:** Shorya Awtar, Nishant Mangesh Jalgaonkar, Daniel Sousa Schulman
- **Number:** 2024-026
  - **Title:** Preemptive stimuli to occupants of a Moving Vehicle
  - **Inventors:** Shorya Awtar, Nishant Mangesh Jalgaonkar, Daniel Sousa Schulman
- **Number:** 2026-233
  - **Title:** Systems and Methods Implemeting Perception and Prediction Multithreaded Architecture for Preemptive Control of Active Devices and Systems Within a Vehicle
  - **Inventors:** Shorya Awtar, Daniel Sousa Schulman, Siyuan Yin, Bradley Kerr, Enxu Liu, Anik Ghosh
- **Number:** 2026-234
  - **Title:** Systems and Methods for Preemptive Control of Active Notification Devices and Systems Within a Vehicle
  - **Inventors:** Shorya Awtar, Daniel Sousa Schulman, Siyuan Yin, Bradley Kerr, Enxu Liu, Anik Ghosh
- **Number:** 2026-235
  - **Title:** Systems and Methods Implemeting Control Logic Software Architecture for Preemptive Control of Active Devices and Systems Within A Vehicle
  - **Inventors:** Shorya Awtar, Daniel Sousa Schulman, Siyuan Yin, Bradley Kerr, Enxu Liu, Anik Ghosh
- **Number:** 2025-633
  - **Title:** Preemptively Controlled Active Seat Mechanism
  - **Inventors:** Shorya Awtar, Daniel Sousa Schulman, Gerardo Sierra Reyes, Micale Garland, Elijah Grewell, Philip Stolarski, Alex Wochna, Siyuan Yin, John Harkleroad, Vasu Murthy, Todd Muck, Hamshivraj Dhamrat

Net Effects:

- Worldwide exclusive
- Patents
- All Fields of use
- Right to commercialize

Agreement Terms:

Motion Sync Technologies Inc. will:

- Obtain the right to grant sublicenses
- Pay a royalty on sales
- Reimburse patent costs

The University will:

- Receive equity in Motion Sync Technologies Inc.
- Retain the right to purchase more equity in Motion Sync Technologies Inc.

University Employee; University Title; Relationship with Motion Sync Technologies Inc.

- Shorya Awtar; Professor, Mechanical Engineering; Partial Owner

Agreement #3

License Agreement between the University and Ret Therapeutics, Inc.

Reviewed by the Medical School Conflict of Interest Board

Background:

Ret Therapeutics, Inc. was formed to commercialize IP related to small molecules for treating peripheral neuropathy and desires to license the University's rights associated with the technology listed above.

Innovation Partnerships Intellectual Property File Information:

- **Number:** 2020-313
- **Inventors:** Gabriel Corfas, Andrew White, Jason Rech
- **Title:** Small Molecule Positive Modulators of Ligand-Induced Ret Signaling

Net Effects:

- Worldwide exclusive
- Patents
- Therapeutics
- Right to commercialize

Agreement Terms:

Ret Therapeutics will:

- Obtain the right to grant sublicenses
- Pay a royalty on sales
- Reimburse patent costs

The University will:

- Retain ownership of the licensed technology
- Receive equity in Ret Therapeutics
- Retain the right to purchase more equity in Ret Therapeutics

University Employee; University Title; Relationship with Ret Therapeutics:

- Gabriel Corfas; Professor and Director, Kresge Hearing Institute; Partial Owner

Agreement #4

License Agreement between the University and Y-Reproductive Technologies

Reviewed by the Medical School Conflict of Interest Board

Background:

Y-Reproductive Technologies was formed to commercialize intellectual property that describes development of artificial testes for the purpose of studying and treating male infertility.

Innovation Partnerships Intellectual Property File Information:

- **Number:** 2024-053
    - **Title:** Generation of tests like somatic cell organoids
    - **Inventors:** Sue Hammoud and Umesh Kumar
- **Number:** 2021-502
    - **Title:** Generation of human sertoli cells to support in vivo and in vitro gametogenesis
    - **Inventors:** Sue Hammoud, Umesh Kumar, Veda Yadegiri, and Jun Li
- **Number:** 2025-659
    - **Title:** Development of complex miniature testis
    - **Inventors:** Sue Hammoud, Umesh Kumar, and Lindsay Moritz

Net Effects:

- Worldwide exclusive
- Patents
- Human therapeutics
- Commercialization

Agreement Terms:

Y-Reproductive Technologies will:

- Retain the right to grant sublicenses

The University will:

- Retain ownership of the licensed technology
- May receive equity in Y-Reproductive Technologies
- May retain the right to purchase more equity in Y-Reproductive Technologies

University Employee; University Title; Relationship with Y-Reproductive Technologies:

- Saher (Sue) Hammoud, Associate Professor, Human Genetics, Medical School; Owner